Accolade and Transcarent announce HSR waiting period expiration for merger

Written by Emily J. Thompson, Senior Investment Analyst

ACCD%

Updated: Feb 24 2025

0mins

Merger Announcement: Accolade and Transcarent have announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act regarding their merger.
Completion Timeline: The merger is expected to be completed in Q2, pending Accolade stockholder approval and other customary closing conditions.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Accolade and Transcarent announce HSR waiting period expiration for merger

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Organon (OGN) Receives FDA Approval for Nexplanon Label Expansion to 5 Years

VanEck Increases Strategy Holdings, Responds to NYT Report

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch